IgE, allergy, and risk of glioma: Update from the San Francisco Bay Area Adult Glioma Study in the Temozolomide era

International Journal of Cancer

Volumn 125, Issue 3, 2009, Pages 680-687

  Wiemels, Joseph L ^a   Wilson, David ^b   Patil, Chirag ^c   Patoka, Joseph ^a   McCoy, Lucie ^a   Rice, Terri ^a   Schwartzbaum, Judith ^d   Heimberger, Amy ^e   Sampson, John H ^f   Chang, Susan ^a   Prados, Michael ^a   Wiencke, John K ^a   Wrensch, Margaret ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Allergy; Brain cancer; Epidemiology; Glioblastoma; Glioma; IgE; Temodar; Temozolomide

Indexed keywords

CANCER VACCINE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR VIII VACCINE; IMMUNOGLOBULIN E; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATOPY; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DACARBAZINE; FEMALE; GLIOMA; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOTHERAPY; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SAN FRANCISCO;

EID: 67650071214     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24369     Document Type: Article

References (19)

1. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002;4:278-99.
2. Brenner AV, Linet MS, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD. History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer 2002;99:252-9.
3. Schlehofer B, Blettner M, Preston-Martin S, Niehoff D, Wahrendorf J, Arslan A, Ahlbom A, Choi WN, Giles GG, Howe GR, Little J, Menegoz F, et al. Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Cancer 1999;82:155-60.
4. Schwartzbaum J, Jonsson F, Ahlbom A, Preston-Martin S, Lonn S, Soderberg KC, Feychting M. Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer 2003;106:423-8.
5. Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M. History of allergies among adults with glioma and controls. Int J Cancer 2002;98:609-15.
6. Linos E, Raine T, Alonso A, Michaud D. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst 2007;99:1544-50.
7. Wiemels JL, Wiencke JK, Patoka J, Moghadassi M, Chew T, McMillan A, Miike R, Barger G, Wrensch M. Reduced immunoglobulin E and allergy among adults with glioma compared with controls. Cancer Res 2004;64:8468-73.
8. Wrensch M, Wiencke J, Wiemels J, Miike R, Patoka J, Moghadassi M, McMillan A, Kelsey K, Aldape K, Lamborn KR, Parsa A, Sison JD, et al. Serum IgE, tumor EGFR expression and inherited polymorphisms associated with glioma survival. Cancer Res 2006;66:4531-41.
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
10. Szeinbach SL, Barnes JH, Sullivan TJ, Williams PB. Precision and accuracy of commercial laboratories' ability to classify positive and/or negative allergen-specific IgE results. Ann Allergy Asthma Immunol 2001;86:373-81.
11. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 2008;10:98-103.
12. SAS/STAT software, version 9 of the SAS system for Windows. © 2002-2008 by SAS Institute Inc., Carey, NC, USA.
13. Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Orlow I, Panageas K, Chapman PB. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008;26:2299-304.
14. Anderson HR, Gupta R, Strachan DP, Limb ES. 50 years of asthma: UK trends from 1955 to 2004. Thorax 2007;62:85-90.
15. Isolauri E, Huurre A, Salminen S, Impivaara O. The allergy epidemic extends beyond the past few decades. Clin Exp Allergy 2004;34:1007-10.
16. Von Hertzen LC, Haahtela T. Asthma and atopy-the price of affluence? Allergy 2004;59:124-37.
17. Schaub B, Lauener R, von Mutius E. The many faces of the hygiene hypothesis. J Allergy Clin Immunol 2006;117:969-77.
18. Romagnani S. Coming back to a missing immune deviation as the main explanatory mechanism for the hygiene hypothesis. J Allergy Clin Immunol 2007;119:1511-3.
19. Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH, 2nd. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 2008;152:785-97.